A-B, Representative Western blots for NFATs 1, 2, and 3 in cytosolic (C) and nuclear (N) fractions prepared from hippocampal (A) and cerebellar (B) tissue samples from control, MCI, and AD patients. Histone-3 (His-3) levels were also probed to confirm the purity of nuclear fractions. Note that blots for each protein were derived from different gels. C-H, Percentage of NFAT1, 2, and 3 protein levels (mean ± SD) associated with hippocampal (C-E) and cerebellar (F-H) nuclear fractions from control, MCI, and AD subjects. The results revealed an increase in the association of NFAT1 (C) and NFAT 3 (E) with hippocampal nuclear fractions from MCI, and AD cases, respectively. Relative to hippocampus, changes in NFAT localization in cerebellum were very different. Nuclear accumulation of NFAT1 (F) and NFAT2 (G) was increased, while NFAT3 (H) was decreased with AD. I, Western blot of immunoprecipitated NFAT3 from whole hippocampal homogenates from eight control and eight AD subjects labeled with anti-NFAT3 antibodies and anti-phosphoserine antibodies. J, Mean ± SD band intensity (optical density in arbitrary units) of total NFAT3 and phospho-NFAT3 from subjects shown in panel (I). Results showed that the increased nuclear localization of NFAT3 in AD patients is associated with reduced NFAT3 phosphorylation levels. *p < 0.05, #p < 0.01, +p < 0.001.